TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: insight into the illness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Probability of success at 18 months
Endpoint domain: Mortality/survival
Primary endpoint: venous thromboembolism rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: reoperation for bleeding rates
Endpoint domain: Adverse events/effects
Primary endpoint: Median intestinal transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Constipation-related symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Recurrence rate of pc-BPPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective radiation dose reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRS score change from baseline to final
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Demodex eradication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Quality-Adjusted Life-Year (QALY)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to cord separation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of clinical colds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nasal mucus weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose time in range (TIR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mycologic cure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent affected target toenail
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in paroxysmal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-1 RNA suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posttransfusion RBC recovery and survival
Endpoint domain: Mortality/survival
Primary endpoint: Displacement from setup center
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of radiation isocenter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systolic Blood Pressure (BP) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic Blood Pressure (BP) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Job responsibility changes due to PsA
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of monthly sick days
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: graft patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Symptom scores for cramping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in appetite for salt foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stress-related hemorrhage incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Nosocomial pneumonia incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Emotional appeal
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Source appeal
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Informational appeal
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Development of pressure ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute grade 2 through 4 toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: acute grade 2 through 4 gastrointestinal toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: 3-year retreatment rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Chronic lung disease incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: odynophagia scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained DAS remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained ACR/EULAR Boolean remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained SDAI remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung function (FEV1, FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Longitudinal ε
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Shortening Rate (SR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: specific airway conductance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: forced expiratory flow 25%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: cognitive benefits
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: behavioral benefits
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: global benefits
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: percentage of reflux time (intra‐oesophageal pH < 4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Response rates for LDL-C reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in HDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Optimal spread of local anesthetic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical efficacy of neurostimulator guided rectus sheath block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of first cardiovascular event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reduction in glycated haemoglobin (HbA1c) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma nitrite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: COT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usefulness of the material(s) for asking questions of physicians
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Usefulness of the material(s) for understanding the treatment plan
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Willingness to use the material(s) in the future
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in CTX-I and CTX-II levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic acidosis control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Schirmer's baseline tear secretion test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective evaluation of symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: resection rate after two-stage operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvement of CCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distal surgical margin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Protective ileostomy rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: weekday TV-viewing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: computer/game-use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of HSV DNA sequences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Detection of VZV DNA sequences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: IgG concentrations ≥0.35µg/mL for vaccine serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of children who are pneumococcal carriers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cleansing results (Boston scale scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastrointestinal symptoms (abdominal fullness and colicky pain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Endoscopist fatigue during colonoscopy
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Spontaneous initiation of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Bone formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Clearance parameters of propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First vascular event (VE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial fatty acid utilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Leading follicular diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CU lesions count at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T2 new lesion count at 48 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOD change at 48 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: health status scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Complete remission and partial remission rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: minor complication rates
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in clinical hyperthyroidism symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood thyroid hormone levels decreased to normal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: fibromyalgia severity (FIQR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of life in regards to IBS symptoms (IBS QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: DSST scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Digit Recall task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysphoric mood ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mental performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women gaining gestational weight within recommendations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Steroid-specific side effects
Endpoint domain: Adverse events/effects
Primary endpoint: mechanical ventilation duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global PSQI score improvement
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: sleep efficiency improvement
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: mean corrected count increment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: good response rate to compatible platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Development of oestrogen receptor-positive invasive breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: Development of endocrine symptoms (hot flushes)
Endpoint domain: Adverse events/effects
Primary endpoint: 2-year locoregional control
Endpoint domain: Mortality/survival
Primary endpoint: local/regional failure and persistence of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days dependent in BADL and IADL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time spent in complete dependency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive aspects improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Clinical outcomes (SF-36 MCS and PCS, VAS, JOA, NDI scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean binocular UDVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean binocular UIVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean binocular UNVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: infants with healthy height-for-age measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ADHD‐RS‐IV total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants rated very much/much improved on CGI‐I
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mydriatic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Distensibility and compliance of brachial and femoral arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Altered flow‐dependent vasodilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Urinary 8‐iso‐prostaglandin F2alpha levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-reported difficulty in swallowing function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: arrhythmia free survival
Endpoint domain: Mortality/survival
Primary endpoint: Mean number of draining fistulas per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with healed fistulas at week 56
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Three consecutive weeks of methamphetamine abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention in treatment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Subacute closure of stent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: degree of breathlessness at maximum power output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: maximum power output achieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in junk food consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial leucine balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in 25(OH)D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Baseline BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: tympanic membrane temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: forearm and calf skin-surface temperature gradients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dental plaque MS levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of acid reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Death/recurrent MI
Endpoint domain: Mortality/survival
Primary endpoint: TIMI 3 flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain VAS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: duration of stay in the recovery unit and hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: additional dose requirements
Endpoint domain: Adverse events/effects
Primary endpoint: RSS (Richmond Sedation Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lactate incremental area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: FPA (Flow Per Area)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: neurocognitive decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Burning/stinging symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total cortisol output following CRH challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Baseline cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Success rate of PEG placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of thromboembolic events (TEs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of vessel occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disappearance of HBeAg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Negative HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient engagement
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Retention in care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Anxiety intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relaxation level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Simplified Acute Physiology Score-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain reported in PACU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-1 RNA level less than 50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: persistence or recurrence of BV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensor glucose result < 3.9 mmol/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the 24-h homocysteine-by-time curves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fruit and vegetable servings (FVs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sugar-sweetened beverage servings (SSBs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak oxygen consumption (VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: onset time to T4 sensory level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma triglyceride level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: satiety
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Fat mass (FM) in upper limbs and trunk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat-free mass (FFM) in upper limbs and trunk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical performance (PP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in LVESVi over 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal clearance (CL) of NAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal elimination half-life of NAC in neonates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NAC cord to maternal ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: local relapse-free survival
Endpoint domain: Mortality/survival
Primary endpoint: grade 3-4 toxicity rate
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of patients with treatment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patients' global assessment of dyspeptic symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peripheral-blood CD4-to-CD8 ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: interferon‐γ responses measured by serial QFT‐GIT assays
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain tolerance thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heat pain detection threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes